Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference

BOSTON, June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that data from the Company's CF clinical development programs will be presented during three panel presentations at the 42^nd European Cystic Fibrosis Society (ECFS) Conference on June 5-8, 2019 at the Arena and Convention Centre Liverpool in Liverpool, United Kingdom. The Company will also host an educational symposium on Wednesday, June 5^th from 4:00 to 5:30 p.m. BST, which will be located in Hall 1C.

The event, titled "Reshaping the Landscape of Cystic Fibrosis Treatment Options for People with Cystic Fibrosis – Novel CFTR Modulator Combinations," will feature presentations by key opinion leaders, including:

• Patrick Flume, M.D.
  Professor of Medicine and Pediatrics, Medical University of South Carolina
  Title: The Evolving CFTR Modulator Landscape
  
  
• Jane Davies, M.D.
  Professor of Paediatric Respirology, Imperial College School of Medicine
  Title: Unmet Needs – The Patient Experience 
  
  
• Damian Downey, M.D.
  Clinical Senior Lecturer in Respiratory Medicine, Queen's University Belfast
  Title: New CFTR Modulator Combinations – New Possibilities
  
  
• Jeffrey Beekman, Ph.D.
  Associate Professor & Director of CF Research Lab of Department of Pediatrics, University Medical Center Utrecht
  Title: Personalized Approach to CFTR Modulator Therapy

Details for the presentations are as follows:

Title: Initial Results Evaluating Combinations of the Novel CFTR Corrector PTI-801, Potentiator PTI-808, and Amplifier PTI-428 in CF Subjects
Presenter: Damian Downey, M.D., Clinical Senior Lecturer in Respiratory Medicine, Queen's University Belfast, Belfast, UK
Session Title: Hot off the press: new data from drug trials
Date and time: Thursday, June 6, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1A

Title: Initial Results Evaluating the Add-On Effect of the Novel CFTR Corrector PTI-801 in CF Subjects
Presenter: Manu Jain, M.D., Professor of Medicine (Pulmonary and Critical Care) and Pediatrics, Northwestern Medicine (Feinberg School of Medicine), Chicago, IL, US
Session Title: Hot off the press: new data from drug trials
Date and time: Thursday, June 6, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1A

Title: Initial Results Evaluating the Novel CFTR Corrector PTI-801, Potentiator PTI-808, and Amplifier PTI-428 in F508del Homozygous CF Subjects
Presenter: Geoffrey Gilmartin, M.D., Chief Medical Affairs Officer, Proteostasis, Boston, MA, US
Session Title: Late Breaking Science
Date and time: Friday, June 7, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1C

Following the presentations at ECFS, the PTI presentations will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com.

For more information on this meeting, visit: https://www.ecfs.eu/liverpool2019.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit www.proteostasis.com.

Safe Harbor

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the expected presentations at an upcoming conference.  Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.  Such risks and uncertainties include, without limitation, the uncertainties inherent in the execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies, and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on form 10-Q for the quarter ended March 31, 2019, and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Investors:
David Pitts / Claudia Styslinger
Argot Partners
212.600.1902
[email protected] / [email protected]

Media:
David Rosen
Argot Partners
212.600.1902
[email protected] 

SOURCE Proteostasis Therapeutics, Inc.

Related Links

http://www.proteostasis.com